Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report

被引:109
作者
Comeau, Anne Marie
Accurso, Frank J.
White, Terry B.
Campbell, Preston W., III
Hoffman, Gary
Parad, Richard B.
Wilfond, Benjamin S.
Rosenfeld, Margaret
Sontag, Marci K.
Massie, John
Farrell, Philip M.
O'Sullivan, Brian P.
机构
[1] Cyst Fibrosis Fdn, Bethesda, MD 20814 USA
[2] Univ Massachusetts, Sch Med, New England Newborn Screening Program, Worcester, MA 01605 USA
[3] Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA 01605 USA
[4] Univ Colorado, Hlth Sci Ctr, Dept Pediat, Mike McMorris Cyst Fibrosis Res & Treatment Ctr, Denver, CO 80202 USA
[5] Childrens Hosp, Denver, CO 80218 USA
[6] Univ Wisconsin, State Lab Hyg, Madison, WI USA
[7] Univ Wisconsin, Dept Pediat, Madison, WI USA
[8] Brigham & Womens Hosp, Dept Newborn Med, Boston, MA 02115 USA
[9] Childrens Hosp, Dept Newborn Med, Boston, MA 02115 USA
[10] NHGRI, Behav Res Branch, Bethesda, MD USA
[11] NIH, Warren G Magnuson Clin Ctr, Dept Clin Bioeth, Bethesda, MD 20892 USA
[12] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA
[13] Univ Colorado, Hlth Sci Ctr, Dept Prevent Med, Denver, CO 80202 USA
[14] Royal Childrens Hosp, Dept Resp Med, Melbourne, Vic, Australia
[15] Univ Massachusetts, Med Ctr, Dept Pediat, Worcester, MA 01605 USA
关键词
newborn screening; cystic fibrosis; genotype; sweat test; guidelines;
D O I
10.1542/peds.2006-1993
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Newborn screening for cystic fibrosis offers the opportunity for early intervention and improved outcomes. This summary, resulting from a workshop sponsored by the Cystic Fibrosis Foundation to facilitate implementation of widespread high quality cystic fibrosis newborn screening, outlines the steps necessary for success based on the experience of existing programs. Planning should begin with a workgroup composed of those who will be responsible for the success of the local program, typically including the state newborn screening program director and cystic fibrosis care center directors. The workgroup must develop a screening algorithm based on program resources and goals including mechanisms available for sample collection, regional demographics, the spectrum of cystic fibrosis disease to be detected, and acceptable failure rates of the screen. The workgroup must also ensure that all necessary guidelines and resources for screening, diagnosis, and care be in place prior to cystic fibrosis newborn screening implementation. These include educational materials for parents and primary care providers; systems for screening and for providing diagnostic testing and counseling for screen-positive infants and their families; and protocols for care of this unique population. This summary explores the benefits and risks of various screening algorithms, including complex situations that can occur involving unclear diagnostic results, and provides guidelines and sample materials for state newborn screening programs to develop and implement high quality screening for cystic fibrosis.
引用
收藏
页码:E495 / E518
页数:24
相关论文
共 98 条
  • [1] Complications associated with symptomatic diagnosis in infants with cystic fibrosis
    Accurso, FJ
    Sontag, MK
    Wagener, JS
    [J]. JOURNAL OF PEDIATRICS, 2005, 147 (03) : S37 - S41
  • [2] Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas
    Ahmed, N
    Corey, M
    Forstner, G
    Zielenski, J
    Tsui, LC
    Ellis, L
    Tullis, E
    Durie, P
    [J]. GUT, 2003, 52 (08) : 1159 - 1164
  • [3] ALPER OM, 2005, HUM MUTAT, V25, P223
  • [4] Alper Ozgul M, 2004, Hum Mutat, V24, P353, DOI 10.1002/humu.9281
  • [5] [Anonymous], 2000, Pediatrics, V106, P383
  • [6] Epidemiology and survival analysis of cystic fibrosis in an area of intense neonatal screening over 30 years
    Assael, BM
    Castellani, C
    Ocampo, MB
    Iansa, P
    Callegaro, A
    Valsecchi, MG
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 156 (05) : 397 - 401
  • [7] MILD CYSTIC-FIBROSIS AND NORMAL OR BORDERLINE SWEAT TEST IN PATIENTS WITH THE 3849+10 KB C-]T MUTATION
    AUGARTEN, A
    KEREM, BS
    YAHAV, Y
    NOIMAN, S
    RIVLIN, Y
    TAL, A
    BLAU, H
    BENTUR, L
    SZEINBERG, A
    KEREM, E
    GAZIT, E
    [J]. LANCET, 1993, 342 (8862) : 25 - 26
  • [8] Stature as a prognostic factor in cystic fibrosis survival
    Beker, LT
    Russek-Cohen, E
    Fink, RJ
    [J]. JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, 2001, 101 (04) : 438 - 442
  • [9] Cystic fibrosis mutations and genotype-pulmonary phenotype analysis
    Braun, Andrew T.
    Farrell, Philip M.
    Ferec, Claude
    Audrezet, Marie Pierre
    Laxova, Anita
    Li, Zhanhai
    Kosorok, Michael R.
    Rosenberg, Marjorie A.
    Gershan, William M.
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2006, 5 (01) : 33 - 41
  • [10] *CAL DEP HLTH SERV, BIRTH REC 2003